drugset / Trial / NCT01686620

A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

NCT01686620

Phase 2 Completed 132 enrolled Biodel
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.

Timeline

Start
2012-08
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BIOD-123 Unknown
Comparator Insulin Lispro Protein / enzyme biologic